New Treatment Option Extends CTCL Progression Free Survival

by U.S. Medicine

January 4, 2018

STANFORD, CA — Patients with cutaneous T-cell lymphoma (CTCL) might have a promising new treatment option, according to a study presented at a recent conference.

In a presentation at the 2017 American Society of Hematology Annual Meeting in Atlanta, an international team of researchers outlined results of a phase III study that found mogamulizumab therapy doubled progression free survival in patients with previously treated CTCL compared to the current standard of care, vorinostat.1

Mogamulizumab is a monoclonal antibody directed against chemokine receptor 4 (CCR4), which is overexpressed on malignant T-cells.

“Cutaneous T- cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma,” wrote the Stanford University-led study team, which included participation from the Salt Lake City VAMC. “Patients with CTCL suffer reduced quality of life from intractable itching and recurrent infections. Advanced stages have a poor prognosis.”

In a Phase I-II study in CTCL, mogamulizumab demonstrated a tolerable safety profile with a 37% overall response rate (ORR), and, based on those results, MAVORIC, an open-label, multinational, randomized, Phase III study, was launched to compare the product to vorinostat in previously treated CTCL.

The study, which researchers tout the study as the largest randomized trial and the first pivotal trial to use progression-free survival (PFS) as a primary endpoint in CTCL, enrolled 372 patients with mycosis fungoides (MF) or Sezary syndrome (SS) who had failed at least one systemic therapy. Researchers randomized patients to receive either mogamulizumab or vorinostat; patients in the vorinostat arm could crossover to the investigational arm upon progression or intolerable toxicity.

Participants were randomized 1:1 to mogamulizumab 1.0 mg/kg (weekly for the first four-week cycle and then every two weeks or vorinostat, 400 mg daily. The primary endpoint was defined as progression free survival using a global composite response based on skin, blood, nodes and viscera.

Overall, investigators reported that mogamulizumab improved progression free survival by 47%. Patients receiving mogamulizumab had median progression free survival of 7.7 months compared to 3.1 for patients receiving vorinostat. Independent reviewers found a 36% increase in progression free survival, 6.7 months for mogamulizumab vs 3.8 months for vorinostat.

Mogamulizumab had a much higher objective response rate as well at 28% vs 4.8 for vorinostat. Patients who switched from the vorinostat arm to the mogamulizumab arm had a 30.1% objective response rate.

Patients also reported much greater reduction in symptoms and improvement in functional status on mogamulizumab than vorinostat throughout treatment.

Treatment-emergency adverse events associated with mogamulizumab included infusion-related reactions (33.2%) and skin eruptions (23.9%), neither of which occurred in more than 1% of patients receiving vorinostat. Vorinostat was associated with much higher rates of diarrhea, thrombocytopenia, dysgeusia and elevated blood creatinine, all of which occurred in more than 28% of patients.

Study authors concluded that their study supports mogamulizumab as “a valuable new therapeutic option in patients with CTCL.”

1Kim HK, Bagot M, Pinter-Brown L, Rook AH, et. al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. American Society of Hematology 59th Annual Meeting and Exposition. 2017 Dec 9-12. Atlanta, Georgia.


Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up